CD274 and central nervous system cancer: Based on the expression status of programmed death ligand-1 (PD-L1) and the radiosensitivity gene signature, researchers identified a subgroup of PD-L1-high-RR that could benefit from combined immunotherapy with radiotherapy in low-grade glioma.